Thursday, 2 December 2021
  
Login

Australia's most trusted
source of pharma news

Thursday, 02 December 2021
News

AZ facing tough competition

Posted 24 November 2021 AM

AstraZeneca's new Covid therapy Evusheld will need to hustle for market share in Australia if it wins provisional approval from the TGA, according to new research.

Data analytics company GlobalData has warned "on expected successful provisional approval and launch in early 2022" the company faces competition with a "crowded COVID-19 armory" of monoclonal antibody (mAb) and oral antiviral therapies.

To see the whole article, please login

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.